Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 1,001–1,100 of 2,932
Occurrence of Aspergillus fumigatus azole resistance in soils from Switzerland
Schürch, S., Gindro, K., Schnée, S., Dubuis, P., Codina, J. M., Wilhelm, M., Riat, A., Lamoth, F., & Sanglard, D. (2023) · Medical Mycology · doi:10.1093/mmy/myad110 · Cited by 16
Achilonu, C. C., Davies, A. A., Kanu, O. O., Noel, C. B., & Oladele, R. O. (2023) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-023-00269-4 · Cited by 21
“Over 1.6 million deaths annually are caused by fungal diseases globally, and more than 1 billion people are at extremely high risk from severe fungal infections [2, 3].”
InfluentialSelf-citationInfectious Complications of Pulmonary Sarcoidosis
Valeyre, D., Bernaudin, J., Brauner, M., Nunès, H., & Jeny, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020342 · Cited by 27
“Invasive aspergillosis occurs in severely immunocompromised individuals, while chronic pulmonary aspergillosis is commonly associated with tuberculosis, COPD, and sarcoidosis [36].”
BackgroundExposure to resistant fungi across working environments and time
Kofoed, V. C., Campion, C., Rasmussen, P. U., Møller, S. A., Eskildsen, M. H., Nielsen, J. L., & Madsen, A. M. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.171189 · Cited by 15
Biogenesis, germination, and pathogenesis of Cryptococcus spores
Ortiz, S. C., & Hull, C. M. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00196-23 · Cited by 15
“In contrast, strains harboring deletions of the ISP2 (identified spore protein 2) gene consistently showed increases (~50% more) in spore yield, suggesting some form of mis-regulation during spore formation (53).”
BackgroundInfluentialRíos-López, A. L., Dávila-Aviña, J., González, G. M., & Flores-Maldonado, O. E. (2024) · Current Microbiology · doi:10.1007/s00284-024-03678-w · Cited by 17
“Cases of these invasive mycoses are on the rise, with mortality rates ranging from 50 to 80%, mainly due to the emergence and rapid spread of antifungal-resistant strains and limited access to quality diagnostics and treat-ment [5–7].”
Ghalwash, D. M., Abou‐Bakr, A., Hussein, R. R., & El‐Gawish, A. A. (2024) · The Egyptian Journal of Otolaryngology · doi:10.1186/s43163-024-00614-4 · Cited by 14
Mahfufah, U., Mahfud, M. A. S., Saputra, M. D., Azis, S. B. A., Salsabila, A., Asri, R. M., Habibie, H., Sari, Y. W., Yulianty, R., Alsayed, A. R., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c19482 · Cited by 16
Chen, X., Lin, S., Jin, Q., Zhang, L., Jiang, W., Lu, X., Wang, G., & Ge, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s460702 · Cited by 14
Qin, W., Guo, T., You, T., Tian, R., Cui, X., & Wang, P. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116402 · Cited by 15
Synthesis of current pediatric urinary microbiome research
Jeries, L. M., Sysoeva, T. A., Karstens, L., & Kelly, M. S. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1396408 · Cited by 18
Siderophore-Conjugated Antifungals: A Strategy to Potentially Cure Fungal Infections
Lakshminarayanan, K., Murugan, D., Venkatesan, J., Thirumalaiswamy, H. V., Gadais, C., & Rangasamy, L. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00046 · Cited by 14
Kulig, K., Rąpała‐Kozik, M., & Karkowska‐Kuleta, J. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100255 · Cited by 16
“…in different host niches, including the oral cavity, gastrointestinal tract or lower genital tract, but they are also the cause of serious systemic diseases with a mortality rate in the range of 40 – 55 % (Millsop and Fazel, 2016; Bongomin et al., 2017; Pappas et al., 2018; Yano et al., 2019).”
BackgroundHonoré, P. M., Bassetti, M., Cornely, O. A., Dupont, H., Fortün, J., Kollef, M. H., Pappas, P. G., Pullman, J. R., Vázquez, J. A., Bielicka, I., et al. (2024) · Critical Care · doi:10.1186/s13054-024-05152-2 · Cited by 19
“Worldwide, there are an estimated 700,000 cases of IC each year [6].”
New Mitochondrial Targets in Fungal Pathogens
Murante, D., & Hogan, D. A. (2019) · mBio · doi:10.1128/mbio.02258-19 · Cited by 17
“Invasive candidiasis affects approximately 700,000 individuals worldwide on a yearly basis and has a mortality rate of 19 to 24% (1).”
BackgroundManifestations of pulmonary aspergillosis in pediatrics
Chacko, A., & Moss, R. B. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000898 · Cited by 14
“alent than acute invasive aspergillosis [4].”
Ferreras-Antolin, L., Bielicki, J. A., Warris, A., Sharland, M., & Hsia, Y. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002983 · Cited by 13
Cryptococcal Virulence in Humans: Learning From Translational Studies With Clinical Isolates
de Sousa, H. R., Frazão, S. D. O., de Oliveira, G. P., Albuquerque, P., & Nicola, A. M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.657502 · Cited by 13
“The genus Cryptococcus is one of the deadliest among those that cause systemic mycoses in humans (Bongomin et al., 2017).”
BackgroundThe burden of serious fungal infections in Sierra Leone: a national estimate
Lakoh, S., Orefuwa, E., Kamara, M. N., Jiba, D. F., Kamara, J. B., Kpaka, S., & Denning, D. W. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211027996 · Cited by 13
Self-citationHussain, A., Alshehri, S., Ramzan, M., Afzal, O., Altamimi, A. S. A., & Alossaimi, M. A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102699 · Cited by 13
The yapsin family of aspartyl proteases regulate glucose homeostasis in Candida glabrata
Askari, F., Rasheed, M., & Kaur, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101593 · Cited by 20
“Candida species are themost common fungal pathogens that cause invasive infections in immunocompromised humanhosts, with these infections associated with high economic burden, morbidity, and mortality (7, 8).”
BackgroundSmall molecule based anti-virulence approaches against Candida albicans infections
Kalimuthu, S., Alshanta, O. A., Krishnamoorthy, A. L., Pudipeddi, A., Solomon, A. P., McLean, W., Leung, Y. Y., Ramage, G., & Neelakantan, P. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.2025337 · Cited by 14
“Over 500 million people in the world suffer from candidiasis (Bongomin et al. 2017) with an increasing mortality rate of 5–71% (Moran et al. 2009).”
BackgroundAlbehaijani, S. H. I., Macreadie, I. G., Morrissey, C. O., & Boyce, K. J. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac033 · Cited by 14
Andriani, G. M., Spoladori, L. F. D. A., Fábris, M., Camargo, P. G., Pereira, P. M. L., Santos, J. P., Bartolomeu-Gonçalves, G., Alonso, L., Lancheros, C. A. C., Alonso, A., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1040671 · Cited by 17
“5 million people die yearly due to fungal infections (Bongomin et al., 2017).”
BackgroundAcquired resistance in fungi: how large is the problem?
Roilides, E., & Iosifidis, Ε. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.018 · Cited by 14
Fungal Diseases in Taiwan—National Insurance Data and Estimation
Huang, Y., Denning, D. W., Shih, S.-M., Hsiung, C. A., Wu, U., Sun, H., Chen, P., Chen, Y., & Chang, S. (2019) · Journal of Fungi · doi:10.3390/jof5030078 · Cited by 16
“Burdens of fungal disease vary widely by pathogen, types of infection, patient populations and country/region [1].”
Self-citationScordino, F., Giuffrè, L., Felice, M. R., Orlando, M. G., Medici, M. A., Marino‐Merlo, F., & Romeo, O. (2019) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2019.104068 · Cited by 13
Cholic-Acid-Derived Amphiphiles Can Prevent and Degrade Fungal Biofilms
Gupta, R., Thakur, J., Pal, S., Mishra, D., Rani, P., Kumar, S., Saini, A., Singh, A. K., Yadav, K., Srivastava, A., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01221 · Cited by 13
Prohaska, S., Henn, P., Wenz, S., Frauenfeld, L., Rosenberger, P., & Haeberle, H. A. (2020) · BMC Anesthesiology · doi:10.1186/s12871-020-01031-9 · Cited by 14
Identification and Characterization of a Neutral Locus for Knock-in Purposes in C. parapsilosis
Németh, T., Papp, C., Vágvölgyi, C., Chakraborty, T., & Gácser, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01194 · Cited by 13
“…knock-in, overexpression, reintegration, genetic manipulation, GFP INTRODUCTION Fungal infections represent a global threat with nearly one billion cases per year ranging from mild superficial to invasive infections with high mortality rates (Pfaller and Diekema, 2007; Bongomin et al., 2017).”
BackgroundMicrobiome-mediated regulation of anti-fungal immunity
Zelante, T., Costantini, C., & Romani, L. R. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.05.002 · Cited by 14
“The fungi that seem to cause severe human fungal diseases include the airborne fungus Aspergillus fumigatus, which induces chronic pulmonary Aspergillosis, invasive aspergillosis, fungal asthma and keratitis; the encapsulated fungus Cryptococcus neoformans that induces cryptococcal meningitis complicating HIV/AIDS; th…”
BackgroundCarradori, S., Ammazzalorso, A., Filippis, B. D., Şahin, A. F., Akdemir, A., Орехова, А. В., Bonincontro, G., & Simonetti, G. (2022) · Antibiotics · doi:10.3390/antibiotics11101375 · Cited by 14
“Pathogens such as Candida and Aspergillus, which are responsible for resilient ever-growing and invasive fungal infections, contribute to high mortality rates all over the world [2,3].”
BackgroundCalcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2022) · Journal of Fungi · doi:10.3390/jof8101102 · Cited by 12
Antifungal resistance in yeasts from One Health perspective: A Brazilian study
Bastos, R. W., Peres, N. T. A., da Silva, K. J. G., Gouveia‐Eufrásio, L., de Carvalho, D. S., Cruz, G. S., Lucini, F., Silva, L. S., Silva, S. E., Vechi, H. T., et al. (2025) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2025.179139 · Cited by 13
Prospective on Alkaloids-based sustainable methods to treat fungal pathogens: a comprehensive review
Saket, A., Choudhary, H., Singh, S., Shukla, A. K., & Srinivasan, T. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04381-5 · Cited by 15
“Fungal infections are responsible for substantial global morbidity and mortality, affecting over one billion people annually (Rayens and Norris 2022; Bongomin et al. 2017).”
Population structure in a fungal human pathogen is potentially linked to pathogenicity
Hatmaker, E. A., Barber, A. E., Drott, M. T., Sauters, T. J. C., Gumilang, A., Alastruey‐Izquierdo, A., Garcia‐Hermoso, D., Eagan, J. L., Keller, N. P., Kontoyiannis, D. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62777-9 · Cited by 15
“Five populations of A. fl avus were identi fi ed, with clinical isolates overrepresented in one population For genomes from clinical isolates sequenced in this study, short-read sequencing resulted inover 10million paired-end reads for each of the isolates (Supplemental Data 2).”
InfluentialFungal asthma among Ugandan adult asthmatics
Kwizera, R., Bongomin, F., Olum, R., Meya, D. B., Worodria, W. O., Bwanga, F., Fowler, S. J., Gore, R. B., Denning, D. W., & Kirenga, B. (2021) · Medical Mycology · doi:10.1093/mmy/myab023 · Cited by 12
Self-citationLam, L. M. T., Ismail, A. A., Lévesque, S., Dufresne, S. F., Cheng, M. P., Vallières, É., Luong, M., Sedman, J., & Dufresne, P. J. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01398-21 · Cited by 14
The Use of Host Biomarkers for the Management of Invasive Fungal Disease
Griffiths, J. S., Orr, S. J., Morton, C. O., Loeffler, J., & White, P. L. (2022) · Journal of Fungi · doi:10.3390/jof8121307 · Cited by 11
Quantitative and Qualitative Airborne Mycobiota Surveillance in High-Risk Hospital Environment
Górzyńska, A., Grzech, A., Mierzwiak, P., Ussowicz, M., Biernat, M., & Nawrot, U. (2023) · Microorganisms · doi:10.3390/microorganisms11041031 · Cited by 13
“Improved diagnostics of IFD has revealed multiple other risk groups, such as patients with exacerbated chronic obstructive pulmonary disease (COPD), who show invasive aspergillosis in up to 4% of cases [11].”
BackgroundInfluentialZhang, X. R., Ma, T., Wang, Y. C., Hu, S., & Yang, Y. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04912-22 · Cited by 12
Raposo, B. L., Souza, S. O., de Santana, G. S., Lima, M. T., Sarmento-Neto, J. F., Reboucas, J. S., Pereira, G., Santos, B. S., Filho, P. E. C., Ribeiro, M. S., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s404422 · Cited by 12
“albicans appears as the main cause of candidiasis and is among the most frequent mucocutaneous pathogens.(19) This fungus can cause opportunistic infections, especially in susceptible persons, such as those undergoing immunosuppressing or antibiotic therapies, cancer treatment, diabetic patients, pregnant women, as we…”
Backgroundda Silva, C. R., Sá, L. G. D. A. V., Ferreira, T. L., Leitão, A. C., Cabral, V. P. D. F., Rodrigues, D. S., Barbosa, A. D., Moreira, L. E. A., Filho, H. L. P., Neto, J. B. D. A., et al. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101431 · Cited by 12
An insight into new strategies and targets to combat antifungal resistance: A comprehensive review
Nahar, D., Mohite, P. B., Lonkar, A., Chidrawar, V. R., Dodiya, R., Uddin, M. J., Singh, S. K., & Prajapati, B. G. (2023) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2023.100120 · Cited by 23
Thakur, R., Shishodia, S. K., Sharma, A., Chauhan, A., Kaur, S., & Shankar, J. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100220 · Cited by 16
“This susceptibility has increased due to factors such as augmented transplantation cases, cancer occurrences, and disorders leading to immune suppression (Bongomin and Gago, 2017).”
BackgroundInfluentialMulticentric Study on the Clinical Mycology Capacity and Access to Antifungal Treatment in Portugal
Fernandes, R., Sabino, R., Cunha, C., Cornely, O. A., Carvalho, A., Salmanton‐García, J., PT Group for IFI Management Capacity, Batista, J., Carvalho, D., Coutinho, A., et al. (2024) · Mycopathologia · doi:10.1007/s11046-024-00830-9 · Cited by 12
Zubair, M., Husain, F. M., Alamri, M. M., Hasan, I., Hassan, I., Albalawi, T., Fatima, F., Khan, A., Arshad, M., Alam, P., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1322778 · Cited by 16
Pontes, L., Arai, T., Beraquet, C. A. G., Giordano, A. L. P. L., Reichert‐Lima, F., da Luz, E. A., de Sá, C. F., Levy, L. O., Tararam, C. A., Watanabe, A., et al. (2024) · Journal of Fungi · doi:10.3390/jof10020122 · Cited by 15
“Globally, it affects approximately 8 million individuals annually [1,2].”
BackgroundKang, Y., Li, Q., Yao, Y., Xu, C., Qiu, Z., Jia, W., Li, G., & Wang, P. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s440363 · Cited by 14
“39,40 44 Our study conducted in Ningxia province, China, observed an increase in the number of identified A. fumigatus strains from 2021 to 2023.”
BackgroundAmsri, A., Pruksaphon, K., Thammasit, P., Nosanchuk, J. D., & Youngchim, S. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1367656 · Cited by 12
Wang, C., Miller, N., Vines, D., Severns, P. M., Momany, M., & Brewer, M. T. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.02056-23 · Cited by 15
Lyu, S., Zhang, T., Peng, P., Cao, D., Ma, L., Yu, Y., Dong, Y., Qi, X., & Wei, C. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.6.13 · Cited by 13
Rafanomezantsoa, L. C., Sabourin, E., Sebbouh, N. G., Sitterlé, E., Halima, N. B., Raveloarisaona, Y. S., Quesne, G., Dannaoui, É., & Bougnoux, M. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03585-23 · Cited by 14
Kim, Y., Guk, T., Jang, M.-K., Park, S., & Lee, J. R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135402 · Cited by 13
Chamas, A., Svensson, C., Maneira, C., Sporniak, M., Figge, M. T., & Lackner, G. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00466 · Cited by 15
Wang, L., Liu, Z., Du, X., Song, M., Liang, Z. C., Gao, X., Lu, G., Chang, W., & Zhai, G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106365 · Cited by 14
Wang, Y., Cui, X., Tian, R., & Wang, P. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03381-3 · Cited by 13
“In addition, owing to the presence of multiple virulence factors and complex pathogenic mechanisms of Aspergillus , the prognosis of Aspergillus is poor, and the mortality rate is as high as 30-95% [4, 5].”
BackgroundShowkat, S., Dharumadurai, D., & Kumar, T. S. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107104 · Cited by 15
Three new asexual Kirschsteiniothelia species from Guizhou Province, China
Xiao, X.-J., Liu, N.-G., Ma, J., Zhang, L.-J., Bao, D.-F., Bai, S., Al-Otibi, F. O., Hyde, K. D., & Lu, Y. (2025) · MycoKeys · doi:10.3897/mycokeys.113.139427 · Cited by 14
“Due to the limited number of studies on mycoses, public awareness of fungal infections remains low (Denning 2016; Bongomin et al. 2017; Pegorie et al. 2017; Boniche et al. 2020).”
Weng, J., Du, X., Fang, B., Li, Y., Huang, L., & Yang, J. D. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10627-w · Cited by 16
Revealing the dynamics of fungal disease with proteomics
Sá, M. C. E. A., da Silva, M., Ball, B., & Geddes‐McAlister, J. (2025) · Molecular Omics · doi:10.1039/d4mo00222a · Cited by 12
Dear medical mycologists, it is time to look outside the box
Morio, F. (2019) · FEMS Yeast Research · doi:10.1093/femsyr/foz080 · Cited by 13
Strategies of Drug Delivery for Deep Fungal Infection: A Review
Ma, Z., Wang, X., & Li, C. (2020) · Pharmaceutical Nanotechnology · doi:10.2174/2211738508666200910101923 · Cited by 13
Wang, D., Zhang, W., Ju, J.-X., Wang, L.-J., Huang, R., Xu, Y., Zhang, H., & Qi, J. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.12.004 · Cited by 15
Synthesis and Study of Antifungal Properties of New Cationic Beta-Glucan Derivatives
Kamiński, K., Skóra, M., Krzyściak, P., Stączek, S., Zdybicka‐Barabas, A., & Cytryńska, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090838 · Cited by 13
Dahlman, A., Puthia, M., Petrlová, J., Schmidtchen, A., & Petruk, G. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01032-21 · Cited by 17
Lin, J., Lin, Y., Huang, Y., & Hu, J. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108731 · Cited by 13
Figueiredo, A. B. C., Fonseca, F. L., Kuczera, D., Conte, F. D. P., Arissawa, M., & Rodrigues, M. L. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01181-21 · Cited by 14
“Aproximately 30% of patients diagnosed with histoplasmosis living with HIV/AIDS die in Latin America (2).”
BackgroundLeepattarakit, T., Tulyaprawat, O., Vongseenin, C., Rujirachun, P., Wattanachayakul, P., Phichinitikorn, P., Phoompoung, P., & Ngamskulrungroj, P. (2022) · Mycoses · doi:10.1111/myc.13429 · Cited by 12
New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets
Brankiewicz, W., Okońska, J., Serbakowska, K., Lica, J. J., Dráb, M., Ptaszyńska, N., Łęgowska, A., Rolka, K., & Szweda, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040693 · Cited by 13
“The fungal infections have a major impact on quality of life and also exhibit high levels of mortality [1].”
BackgroundReducing the off-target endocrinologic adverse effects of azole antifungals—can it be done?
Balcerek, M. I., Stewart, A. G., Chapman, P. R., & Lazarus, S. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106587 · Cited by 16
Bansal, S., Vu, K., Liu, R., Ajena, Y., Xiao, W., Menon, S., Bennett, A. B., Gelli, A., & Lam, K. S. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00019 · Cited by 13
Fissel, J. A., Holdren-Serrell, C. K., Memon, W., & Zhang, S. X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.915049 · Cited by 13
“…need for the rapid diagnosis of infectious fungal diseases (Pfaller and Diekema, 2007; Erjavec et al., 2009; Zhang et al., 2021) since this patient population is at high risk of fungal infections and severe disseminated mycoses (Bongomin et al., 2017; Terrero-Salcedo and PowersFletcher, 2020).”
BackgroundCordero-Díaz, A., Robledo-Leal, E., Hernandez‐Fernandez, E., Hernández‐Núñez, E., Elizondo-Zertuche, M., & López-Cortina, S. (2022) · Molecules · doi:10.3390/molecules27123886 · Cited by 12
“However, public health programs in charge of monitoring fungal diseases are generally lacking in timely identification as well as treatment [4]; in fact, most public institutions around the world do not carry out mandatory surveillance of infections caused by fungi [5].”
BackgroundMendonça, A., Carvalho-Pereira, J., Franco‐Duarte, R., & Sampaio, P. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00595-1 · Cited by 13
“The main etiologic agent of invasive aspergillosis is Aspergillus fumigatus, which is associated with more than 300,000 cases per year [3, 4] and a mortality rate of 30–70% [3, 5, 6].”
BackgroundArtemisinin Targets Transcription Factor PDR1 and Impairs Candida glabrata Mitochondrial Function
Zhu, P., Yue, C., Zeng, X., & Chen, X. (2022) · Antioxidants · doi:10.3390/antiox11101855 · Cited by 18
“5 million people being infected every year [1,2].”
BackgroundExisting and emerging therapies for the treatment of invasive candidiasis and candidemia
Bels, D. D., Maillart, E., Bambeke, F. V., Redant, S., & Honoré, P. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2142207 · Cited by 12
“epidemiological survey estimated the global number of patients with invasive candidiasis to 750,000 [5].”
BackgroundSalih, E. Y. A., Julkunen‐Tiitto, R., Luukkanen, O., & Fyhrqvist, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112469 · Cited by 16
“krusei [12,14], and the incidence of serious Candida infections is increasing [15].”
BackgroundMolecular Diagnosis of Endemic Mycoses
Valero, C., Martín-Gómez, M. T., & Buitrago, M. J. (2022) · Journal of Fungi · doi:10.3390/jof9010059 · Cited by 14
“With approximately 40,000 new cases every year sporotrichosis is considered the most prevalent EM in South America, and the most frequent EM in regions of Southern Brazil [14].”
BackgroundAvula, P. R., Chettupalli, A. K., Chauhan, V., & Jadi, R. K. (2023) · Materials Today Proceedings · doi:10.1016/j.matpr.2023.06.282 · Cited by 29
Diagnosis and treatment of fungal keratitis. Part I
Skryabina, Y. V., Astakhov, Y. S., Станиславовна, К. Я., Kasymov, F. O., Zumbulidze, N. G., Сергеевна, В. Т., Petukhov, V. P., Pirgunova, A. A., Masian, J., Климко, Н. Н., et al. (2018) · Ophthalmology Reports · doi:10.17816/ov11363-73 · Cited by 13
Cordeiro, R. D. A., Evangelista, A. J. D. J., Serpa, R., de Andrade, A. R. C., Mendes, P. B. L., de Oliveira, J. S., de Alencar, L. P., Pereira, V. S., de Lima-Neto, R. G., Brilhante, R. S. N., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01337 · Cited by 13
“Thus, antibiotic therapy is a determining risk factor for the development of IFI in immunocompromised patients (Bongomin et al., 2017).”
BackgroundRaval, K. M., Ghormade, V., Rajamohanan, P. R., Choudhary, H., Rudramurthy, S. M., Chakrabarti, A., & Paknikar, K. M. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001040 · Cited by 12
Simões, D., Caetano, L. A., Veríssimo, C., Viegas, C. S. B., & Sabino, R. (2019) · International Journal of Environmental Health Research · doi:10.1080/09603123.2019.1650903 · Cited by 15
“In fact, globally, Aspergillus is estimated to be responsible for causing health issues to millions of people annually (Bongomin et al. 2017; Antunes 2018).”
BackgroundMotamedi, M., Saharkhiz, M. J., Pakshir, K., Akbarabadi, S. A., Khordshami, M. A., Asadian, F., Zareshahrabadi, Z., & Zomorodian, K. (2020) · Current Medical Mycology · doi:10.18502/cmm.5.4.2162 · Cited by 15
Detecting Green Mold Pathogens on Lemons Using Hyperspectral Images
Vashpanov, Y., Heo, G., Kim, Y., Venkel, T., & Son, J. (2020) · Applied Sciences · doi:10.3390/app10041209 · Cited by 12
van Schalkwyk, E., Mhlanga, M., Maphanga, T. G., Mpembe, R. S., Shillubane, A., Iyaloo, S., Tsotetsi, E., Pieton, K., Karstaedt, A., Sahid, F., et al. (2020) · Mycoses · doi:10.1111/myc.13071 · Cited by 12
Noval, C., Ruiz, S., Gonçalves, D. D. S., Ferreira, M. D. S., Honorato, L., Peralta, J. M., Nimrichter, L., & Guimaraes, A. J. (2020) · Journal of Fungi · doi:10.3390/jof6040250 · Cited by 14
“>300,000 cases, with an associated mortality ranging from 30 to 80% [11].”
BackgroundPerlatti, B., Lan, N., Xiang, M., Earp, C. E., Spraker, J. E., Harvey, C. J. B., Nichols, C. B., Alspaugh, J. A., Gloer, J. B., & Bills, G. F. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab022 · Cited by 14
“Although many immunosuppressed populations are at risk for infections due to Cryptococcus species, there were an estimated 220 000 annual cases of C. neoformans infections in 2017 worldwide, and up to a 75%mortality rate, specifically in patients with AIDS (Bongomin et al., 2017; Rajasingham et al., 2017).”
BackgroundFungal Extracellular Vesicles in Pathophysiology
Garcia‐Ceron, D., Bleackley, M. R., & Anderson, M. A. (2021) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-67171-6_7 · Cited by 13
Khan, D., Nile, A. H., Tripathi, A., & Bankaitis, V. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136754 · Cited by 12
Guanylation Significantly Enhances the Antifungal Activity of Poly(α-lysine)
Liu, H., Han, M., Liu, X., & Ji, S. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c01205 · Cited by 15
Angelis, G. D., Menchinelli, G., Torelli, R., Carolis, E. D., Posteraro, P., Sanguinetti, M., & Posteraro, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226467 · Cited by 12
“Fungal infections such as mucosal/skin infections, though non-lethal, can reduce the quality of life for>1 billion affected people [2].”
BackgroundGlucose Metabolism and Use of Alternative Carbon Sources in Medically-Important Fungi
Chew, S. Y., & Than, L. T. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819990-9.00068-8 · Cited by 19
Diagnosing invasive fungal infections in the laboratory today: It's all good news?
Pemán, J., & Gaitán, A. C. R. (2025) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2025.01.004 · Cited by 21
“If pathogenic fungi cannot be detected through culture or histopathological methods, a probable diagnosis of IFI can be established using serological, molecular, and other advanced techniques, along with an assessment of host factors and the clinical condition of the patient (Table 1).”
Octenidine effectively reduces Candida auris colonisation on human skin
Cerbu, D., Seiser, S., Phan-Canh, T., Moser, D., Freystätter, C., Matiasek, J., Kuchler, K., & Elbe‐Bürger, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-11914-x · Cited by 11
Kinetic and Structural Characterization of Sialidases (Kdnases) from Ascomycete Fungal Pathogens
Nejatie, A., Steves, E., Gauthier, N., Baker, J., Nesbitt, J., McMahon, S. A., Oehler, V., Thornton, N. J., Noyovitz, B., Khazaei, K., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00666 · Cited by 11
Impact of Fungi on the World Economy and Its Sustainability: Current Status and Potentials
Singh, I., & Thakur, P. (2023) · Springer eBooks · doi:10.1007/978-981-19-9103-5_1 · Cited by 28
McKenna, J. A., Garcia‐Ceron, D., Bleackley, M. R., Yu, L., Bulone, V., & Anderson, M. A. (2023) · Journal of Extracellular Biology · doi:10.1002/jex2.82 · Cited by 13
“However, the estimated 750,000 annual cases of invasive candidiasis are of the highest concern as these infections contribute most to the morbidity and mortality (Bongomin et al., 2017).”
BackgroundInfluentialTheiaEuk: a species-agnostic bioinformatics workflow for fungal genomic characterization
Ambrosio, F. J., Scribner, M. R., Wright, S. M., Otieno, J. R., Doughty, E. L., Gorzalski, A. J., Siao, D. D., Killian, S., Hua, C. N., Schneider, E., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1198213 · Cited by 15
“Microbial fungal pathogens are a major public health concern estimated to affect over 13 million patients annually, with mortality of over 1 million patients annually (1, 2).”
BackgroundMethod
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.